Dengue

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

EMA approval · 2026-08-19
EMA Authorised: Qdenga (Dengue virus, serotype 2, expressing Dengue virus, serotype 1, surface proteins, live, attenuated;Dengue virus, serotype 2, expressing Dengue virus, serotype 3, surface proteins, live, attenuated;Dengue virus, serotype 2, expressing Dengue virus, serotype 4, surface proteins, live, attenuated;Dengue virus, serotype 2, live, attenuated) — Takeda Pharmaceuticals International AG Ireland Branch
The EMA has authorised Qdenga, a live attenuated tetravalent dengue vaccine (serotypes 1, 2, 3, 4) by Takeda, for dengue prevention.
EMA approval · 2026-01-30
EMA Authorised: Qdenga (Dengue virus, serotype 2, expressing Dengue virus, serotype 1, surface proteins, live, attenuated;Dengue virus, serotype 2, expressing Dengue virus, serotype 3, surface proteins, live, attenuated;Dengue virus, serotype 2, expressing Dengue virus, serotype 4, surface proteins, live, attenuated;Dengue virus, serotype 2, live, attenuated) — Takeda Pharmaceuticals International AG Ireland Branch
The European Medicines Agency authorised Qdenga, a live attenuated tetravalent dengue vaccine from Takeda, for protection against dengue dis…